Q-omics provides the consensus-scored RPS2P18 profile across patient tissues and cancer cell-line models. RPS2P18 expression is associated with patient survival in 17 of 34 cancer types, with the highest sampling consensus in CESC. Among the 18 cancer types available for tumor–normal comparison, RPS2P18 is differentially expressed in 6, with the highest sampling consensus in HNSC. Additionally, RPS2P18 RNA expression shows 5,547 significant pathway-activity associations, with the highest sampling consensus in UCEC. Together, these results highlight CESC, HNSC, and UCEC as cancer lineages where RPS2P18 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPS2P18 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPS2P18 survival associations across molecular data types. RPS2P18 RNA expression shows survival associations in the most cancer types (17). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPS2P18 RNA expression–survival associations across cancer types. High RPS2P18 expression shows unfavorable associations in THYM, ACC and OV, but favorable associations in CESC, LUSC and READ. The CESC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .006). Together, the overview and detailed table identify CESC as the clearest survival context for RPS2P18 RNA expression.
This table summarizes RPS2P18 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for RPS2P18. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPS2P18 shows higher tumor expression in HNSC, KIRC, KIRP, PRAD, COAD and THCA. The HNSC box plot shows higher RPS2P18 RNA expression in tumor versus normal tissue (log2 FC = +0.065, t-test p < 0.001).
This table shows molecular features associated with RPS2P18 in patient tissues and cancer cell lines. In patient samples, RPS2P18 shows the broadest associations at the RNA and protein expression levels, with UCEC recurring as the lineage with the largest associated feature set.
